Vyvanse Driving Study

The primary objective of the study is to assess the benefice of Vyvanse on the factors that
cause impairments in driving behavior in individuals with ADHD using a driving simulation
aimed at examining the factors that cause impairments in driving behavior in individuals
with ADHD such as driving speed, collision risk, and visual attention of 60 young drivers
(ages 18-24) with ADHD. We hypothesize: 1.) young adults with ADHD treated with Vyvanse
will show lower velocity (speed) scores and spend less time driving over the posted speed
limit in the driving simulation when compared to subjects taking a placebo; 2.) young adults
with ADHD treated with Vyvanse will show a lesser likelihood to collide with a suddenly
appearing peripheral object, less difficulty maintaining the vehicle within their lane, and
a lesser likelihood of driving through stop signs and solid red traffic lights without
slowing down when compared to subjects taking a placebo; and 3.) young adults with ADHD
treated with Vyvanse will exhibit more focused visual attention on details in the visual
field when compared to subjects taking a placebo while driving. In addition, young adults
with ADHD treated with Vyvanse will exhibit less visual tunneling and shorter off-road
glances when compared to subjects taking a placebo.